JonesTrading analyst Soumit Roy has maintained their bullish stance on ORIC stock, giving a Buy rating today.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Soumit Roy has given his Buy rating due to a combination of factors including the potential of Oric Pharmaceuticals to capitalize on recent developments in the prostate cancer treatment landscape. The positive data from Pfizer’s EZH2 inhibitor, mevrometostat, has reinforced the target’s validity in treating prostate cancer, providing a favorable backdrop for ORIC’s own developments in this area. Despite some safety concerns associated with Pfizer’s treatment, ORIC’s early data suggests comparable or better efficacy and safety, albeit from a limited patient sample.
Roy highlights the opportunity for ORIC to benefit from its positioning, as Pfizer’s adjustments to improve safety with dose reductions might create a window for ORIC to establish its own treatment as a competitive option. While more mature data from ORIC is anticipated in the fourth quarter of 2025, the current risk/reward profile presents an attractive buying opportunity. The expectation of further efficacy and safety data supports the recommendation, especially given the potential for ORIC’s candidate to outperform Pfizer’s in certain key metrics.
In another report released today, Wedbush also maintained a Buy rating on the stock with a $20.00 price target.